DENVER, Nov. 6, 2018 /PRNewswire-PRWeb/ -- Today AngelMD has released its findings from the company's quarterly report
The report shows that, generally speaking, the number of investments dropped from Q2 to Q3. However, the total amount of money raised grew significantly, and individual investment sizes averaged over 50 percent higher than in the previous quarter. Leaders in the segment were Bio/Pharma, Medical Device, and Healthcare IT.
"We know how critical it is for AngelMD members to have the right information at their fingertips," said AngelMD CEO Tobin Arthur. "These private healthcare investment reports continue to be a strong tool for allowing our members to make better-educated investment decisions."
The top targeted specialties by amount raised gives some interesting insight into Q3's market shift. While Oncology always receives a large concentration of capital, it was eclipsed in Q3 by General Medicine, Genetics, Immunotherapy, and a few others. Both General Medicine and Genetics look to finish the year ahead of Oncology for total amount of money raised, while Cardiology and Vascular Surgery both enjoy solid investment numbers for the year to date.
A preview of the report is available through the AngelMD blog. The full report is made available to AngelMD Premium members. On top of the quarterly reports, Premium members have access to a host of features that enable better decision making for healthcare investors.
About AngelMD AngelMD is an investment and networking platform connecting innovative medical startups, physicians, investors, and industry partners. Leading physicians from all over the US have joined AngelMD to help source, evaluate and advise companies in biotechnology, medical device, and healthcare technology. For more information, visit http://www.angelmd.co
Subscribe to our Free Newsletters!